Enlivex Therapeutics【ENLV】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.9293

買値

0.9591

売値

0.9999

出来高

0.00 日の範囲 0.00

0.8101 52 週間の範囲 4.59

時価総額

19.404M

前日終値

0.9293

始値

時刻

0.9469

最終取引時間

18:04:10

財務取引量

VWAP

平均取引量 (3 か月)

145,216

発行済株式数

20,880,000

配当利回り

PER

-0.67

1 株当たり利益 (EPS)

-1.39

歳入

純利益

-29.07M

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threate... Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.enlivex.com

本社

Ness Ziona, Center, Isr

設立

Enlivex Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker ENLV. The last closing price for Enlivex Therapeutics was US$0.93. Over the last year, Enlivex Therapeutics shares have traded in a share price range of US$ 0.8101 to US$ 4.59.

Enlivex Therapeutics currently has 20,880,000 shares in issue. The market capitalisation of Enlivex Therapeutics is US$19.40 million. Enlivex Therapeutics has a price to earnings ratio (PE ratio) of -0.67.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Adopts Bitcoin Treasury Reserve Strategy

Nes-Ziona, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Nes-Ziona, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Nes-Ziona, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.1324	-12.4705660733	1.0617	1.1	0.8101	232064	0.9503154	CS
4	-0.6207	-40.0451612903	1.55	1.65	0.8101	175463	1.17245784	CS
12	-0.2907	-23.8278688525	1.22	1.75	0.8101	145216	1.38510877	CS
26	-0.5107	-35.4652777778	1.44	1.75	0.8101	96973	1.37763626	CS
52	-0.8907	-48.9395604396	1.82	4.59	0.8101	116103	2.01900062	CS
156	-6.9607	-88.2217997465	7.89	8.64	0.8101	68228	3.17993017	CS
260	-6.7107	-87.8363874346	7.64	29.4	0.8101	168877	9.23507685	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
RGTIRigetti Computing Inc	US$ 2.74 (57.47%)	15M
QMCOQuantum Corporation	US$ 12.55 (37.46%)	529.98k
TRSTTrustCo Bank Corporation of NY	US$ 48.01 (27.96%)	107
WTBAWest Bancorporation	US$ 30.00 (23.56%)	2
HTBIHomeTrust Bancshares Inc	US$ 45.90 (21.82%)	7
AKTSAkoustis Technologies Inc	US$ 0.0655 (-34.89%)	3.11M
HSTMHealthStream Inc	US$ 25.12 (-21.96%)	6
PFCPremier Financial Corporation	US$ 23.21 (-19.55%)	5
LRHCLa Rosa Holdings Corporation	US$ 0.5543 (-18.50%)	8
INMInMed Pharmaceuticals Inc	US$ 3.82 (-18.03%)	66
RGTIRigetti Computing Inc	US$ 2.74 (57.47%)	15M
ELABElevai Labs Inc	US$ 0.0177 (-11.94%)	5.98M
AKTSAkoustis Technologies Inc	US$ 0.0655 (-34.89%)	3.11M
QUBTQuantum Computing Inc	US$ 7.13 (16.89%)	2.79M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.2118 (11.47%)	1.95M